Deal-Making

Avantor and Cytovance team to address $1.5bn plasmid DNA market

The advanced therapy pipeline is driving demand says Avantor, which has collaborated with Cytovance to offer an expanded plasmid DNA service.  “The demand for plasmid DNA, especially at cGMP-grade, supporting advanced therapeutic modalities is growing rapidly,” said Ger Brophy, EVP of Biopharma Production at Avantor.  He told BioProcess Insider it is being driven by the growing, early-stage pipeline of cell and gene therapies, DNA and RNA vaccines, and gene editing technologies. “We estimate that the total addressable market for plasmid DNA…

Korean CDMO enters US with BMS plant buy

Lotte is set to buy Bristol-Myers Squibb’s (BMS) facility in East Syracuse, which it says will serve its CDMO business in the US. The deal, which is subject to regulatory approvals and other closing conditions, sees Korean-based firm Lotte Corporation acquire BMS’ New York site’s operations and assets. This includes the equipment, property, plant, workforce, and technical capabilities. “This transaction is consistent with our longstanding goal of creating a manufacturing network to best support the ongoing needs of the business…

ALSA latest VC firm to contract Lonza to service its portfolio

Lonza says small to mid-sized companies represent the bulk of its customers as it adds ALSA Ventures’ biopharma portfolio to its client list. European biotech investment firm ALSA has contracted Lonza to help develop and manufacture molecules within its biologics and small molecule company portfolio. The deal, financials of which have not been divulged, will see ALSA’s portfolio companies – which include Promatix, Montis Biosciences, Epsilogen, and Oxford BioTherapeutics – leverage Lonza’s development and manufacturing services and network, along with…

Bora Pharmaceuticals bolsters CDMO biz with Eden buy

As part of its five-year plan, Bora Pharmaceuticals will initially invest $50 million to acquire the CDMO assets of Eden Biologics in Taiwan. Taiwan-based contract development manufacturing organization (CDMO) Bora Pharmaceuticals has said it will initially invest $50 million and up to $100 million to acquire Eden’s CDMO assets. Through the acquisition, Bora will gain assets located in Hsinchu Biomedical Science Park, Taiwan. According to the CDMO, this will build and expand its presence in the biological macromolecule and cell…

Dover shells out $225m for bio-control instruments firm Malema

Biomanufacturing vendor Dover will bolster its Pumps & Process Solutions segment via the addition of Malema’s single-use flow sensor technology. The $225 million cash deal, expected to close in the second quarter, sees Dover add flow-measurement and control instruments maker Malema Engineering Corporation to its service offering. Malema, which is set to make approximately $40-45 million in sales in 2022, produces single-use flow sensors using Coriolis technology which it claims reduces the potential for measurement error and the need for calibration…

PE firm Astorg to buy CordenPharma from ICIG

Astorg Partners has signed an agreement with International Chemical Investors Group (ICIG) to acquire CDMO CordenPharma. According to French private equity firm Astorg, ICIG chose to sell contract development manufacturing organization (CDMO) CordenPharma after a strategic portfolio review, which concluded its aim to focus more on its chemicals portfolio. Under the terms of the deal, ICIG  will reinvest as partners with Astorg to develop CDMO would further. “We look forward to having the opportunity to partner with ICIG and [CordenPharma’s]…

Quell and Cellistic partner to develop cell therapy platform

The aim of the collaboration is to support the expansion of Quell’s autologous T-regulatory (Treg) cell therapy pipeline using Cellistic’s knowledge of iPSC processes. Under the terms of the deal, Quell Therapeutics and human induced pluripotent stem cell (iPSC) technology development and manufacturing firm Cellistic will take part in joint research to form a process for differentiating iPSCs into functional Treg cell therapy products. According to Quell, it will contribute its Treg expertise and technologies, as well as characterizing Treg…

US Gov awards $10.6m freeze-dried plasma contract to Terumo

Terumo Blood and Cell Technologies has won a $10.6 million contract from the US Government to continue freeze-dried plasma (FDP) development. Apheresis services firm Terumo Blood and Cell Technologies has entered into a contract with the Medical Technology Enterprise Consortium (MTEC), which is an Other Transaction Agreement (OTA) with the US Army Medical Research and Development Command. In 2016, Terumo was awarded initial funding of $1.9 million (potential to be increased to $16 million) from the US Government to support…

NorthX Biologics inks vaccine partnership with Abera

NorthX has signed a partnership agreement to upscale and manufacture Abera Biosciences’ vaccine candidate against pneumococcus, Ab-01.12.   Abera is a vaccine and platform development company, which was founded in 2012 as a spinout from Swedish production firm Xbrane Bioscience. Its lead vaccine candidate Ab-01.12 is administered as a nasal spray and aims to treat pneumococcus using technology designed to protect against all variants of the bacterium. Abera is preparing the vaccine candidate for clinical trials in humans and has…

China’s I-Mab allegedly seeking asset or company sale

Shanghai-based I-Mab is in talks with global drugmakers about a potential sale of the whole company or its oncological assets, according to a Bloomberg article. The Bloomberg article claims US and EU pharmas were interested in I-Mab, given its portfolio of 10 clinical stage oncology antibodies plus access to the world’s second largest pharmaceutical market. Bloomberg noted that I-Mab has lost three-fourths of its market value since the prices for pharmaceutical companies peaked in June 2021. When it announced its…